Loading...
Loading...
Retrophin, Inc.
RTRX today announced that it has signed an
agreement with a major pharmaceutical company for the exclusive right to
negotiate a royalty-bearing U.S. license for a product to be developed
for the treatment of Autism and Schizophrenia. Pursuant to the
exclusivity agreement, Retrophin paid the major pharmaceutical company a
non-refundable upfront fee and will have an exclusive period of 120 days
to negotiate a license agreement. Upon execution of a license agreement,
Retrophin would receive the exclusive right to the intellectual property
to develop, manufacture and sell the product in the United States and
would pay an additional fee to the major pharmaceutical company.
Commenting on today's news, Martin Shkreli, Founder, President and Chief
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in